Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data enGene Therapeutics Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2023
FY2024
FY2025
Research and development
15.5
16.5
38.3
94.5
General and administrative
3.96
9.6
24
28.7
Operating expenses
19.4
26.1
62.3
123
Operating income
-19.4
-26.1
-62.3
-123
Interest expense
1.42
4.95
2.8
2.99
Interest income
0.13
1.12
10.4
9.43
Other non-operating income
-5.01
-73.8
7.14
5.86
Pre-tax income
-24.4
-99.9
-55.2
-117
Income tax
0.02
0.02
-0.02
0
Net income
-24.5
-99.9
-55.1
-117
EBITDA
-19.2
-25.9
-62
-123
EPS, basic
44.30
151.22
1.46
2.29
EPS, diluted
44.30
151.22
1.46
2.29
Shares, basic (weighted)
0.66
0.69
37.8
51.1
Shares, diluted (weighted)
0.66
0.69
37.8
51.1
Dividend per share
0.00
0.00
0.00
Balance sheet
FY2023
FY2023
FY2024
FY2025
Cash and equivalents
20.4
81.5
173
50.2
Short-term investments
65.3
144
Other current assets
0.74
1.5
8.63
6.65
Total current assets
22.6
85.4
247
201
Property, plant and equipment
0.39
0.59
1.17
2.48
Lease right-of-use assets
1.74
7.72
Long-term investments
59.5
8.52
Other non-current assets
0.94
0.93
1.37
1.36
Total assets
23.9
87
311
221
Accounts payable
0.72
1.16
1.41
6.69
Accrued liabilities
0.68
0.81
3.48
4.05
Total current liabilities
5.1
5.26
14.7
32
Long-term debt
9.65
9.22
22.5
15.3
Lease liabilities
1.43
6.46
Total liabilities
47.4
14.5
38.6
53.8
Paid-in capital
7.68
13.7
19
27.3
Retained earnings
-99.7
-200
-255
-372
Other comprehensive income
-1.02
-1.02
-1.42
-0.89
Shareholders' equity
-76.6
72.5
273
168
Total equity
-76.6
72.5
273
168
Total liabilities and equity
23.9
87
311
221
Shares outstanding
0.67
23.2
51
52
Cash flow statement
FY2023
FY2023
FY2024
FY2025
Net income
-24.5
-99.9
-55.1
-117
Depreciation and amortization
0.2
0.2
0.3
0.5
Stock-based compensation
0.12
3.45
5.32
9.65
Change in payables
-0.2
0.37
0.47
4.94
Cash from operations
-17.6
-24.7
-48.3
-99.2
Capital expenditures
-0.15
-0.32
-0.93
-1.49
Purchases of investments
-125
-161
Cash from investing
-0.15
-0.32
-126
-25.1
Debt issued
11
22.5
Debt repaid
-1.01
Stock issued
0.01
0.04
0.11
2.22
Dividends paid
0
Cash from financing
28
86.1
266
1.52
Exchange rate effect
-0.81
0
0
0
Net change in cash
9.42
61.1
91.5
-123
Free cash flow
-17.7
-25.1
-49.2
-101
Interest paid
0.62
1.4
1.93
2.29
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to July 31, 2026; growth uses fiscal years. Valuation uses the share price of $1.96 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-56.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-45.2%
Net income / average total assets.
Return on invested capital (ROIC)
-57.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
EPS growth, 1y
56.8%
EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y
-62.7%
Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-38.5%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-28.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
110.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
35.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
327.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
10.2x
Current assets / current liabilities.
Quick ratio
9.79x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
9.79x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.49
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.48
Cash from operations / diluted weighted shares.
Book value per share
$3.44
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.57x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.57x
Market cap / tangible book value, when positive.
FCF yield
-79.2%
Free cash flow / market cap.
Earnings yield
-99.3%
Net income / market cap (the inverse of P/E).
Was enGene Therapeutics Inc. profitable in fiscal 2025?
No. It reported a net loss of $117.3M.
How much free cash flow did enGene Therapeutics Inc. generate in fiscal 2025?
Cash from operations of $99.2M minus capital expenditures of $1.5M left free cash flow of -$100.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.